So he is not up to current male organ growth predictions of 24% - you get by doing nothing. LOL
I have to admire his honesty in sharing his deficiencies.
3 Likes
Your chart gives one star to CR and 3 stars for rapa if given late in life. This is incorrect. CR certainly doesn’t work as well at increasing absolute lifespan when started late than when started earlier, but the magnitude of the remaining lifespan increase is similar when started in old vs. young, and the absolute or remaining increase is greater for CR than it is for rapa when started at the same age. Compare:
40% CR initiated at 19 months of age
“CR extended mean lifespan from 30.7 ± 0.7 (SE) to 35.4 ± 0.8 months (P = .000017) and extended maximum lifespan from 37.6 to 43.6 months (P = 0.000056)”
Rapamycin begun at 19-20 months of age (ITP)
“Expressed as mean lifespan, the effect sizes were 9% for males and 13% for females in the pooled data set.”
Masimum lifespan
Females
Rapamycin 1,245 versus controls 1,094
Males
Rapamycin 1,179 versus controls 1,078
Note also that the mice in the CR study were male, and that the extension of lifespan was greater than for either male or female mice given rapamycin.
(Yes, two different studies, different mouse hybrids, etc. Still).
3 Likes
Thanks for the very informative post! I really appreciate it. One reason why I added one star on it was because of Matt Kaeberlein summary in the topic where he says that it works in around 1/3 of the cases. Is that aligned with your view also?
3 Likes
No: it works in almost all mouse strains, and the ones in which it doesn’t work (or works minimally) are serious freaks. The idea that 1/3 of mouse strains either don’t respond to CR or have their lifespans shortened is based on a very flawed genetic study that has somehow fooled a lot of very intelligent people in the geroscience community.
3 Likes
Really great information! Does there exist any study pointing this out or something else because it seems as you say a big misconception if this is the case. I believe what you are saying but do you have a source that it does not work only in 1/3.of the cases?
Should I change the stars to three instead of one?
1 Like
I use to be a big fan of Dave and Bulletproof; I appreciate his trail-blazing the industry in biohacking our health. But now that we have so much information available via the net, he has become an obsolete source. He, like other older influencers, is trying to reinvent themselves, hanging on to selling or endorsing products that have little to no research behind them, inevitably making them, a "has-been’ in the field of aging.
4 Likes
It’s very sad development when it becomes to sellish everything and that makes it also hard for the users to know what is sales information and not.
1 Like
Its a difficult thing as to how to assess the arguments. If someone has a financial advantage in arguing a particular viewpoint then one has to have some scepticism as to their arguments. However, if someone is not really affected by whether or not people agree with their arguments then they may be so relaxed about the situation that they do not persuade anyone.
3 Likes